# *Bioprosthetic Mitral Valve Thrombosis: 10 Years Single Center Experience*


**Bloch Lev[1], Ilan Bushari Limor[1], Jabaren Mohamed [1], Or Zafrir[1], Orlov Boris[2], Barak Yaron[2], Aravot Dan[2] , Turgeman Yoav[1]**

**[1]Heart Institute , HaEmek Medical Center , Afula**

**[2]Heart Surgery Lady Davis Carmel Hospital , Haifa**

***Conflict of Interest: None***

# *Background:*

- **Mitral valves bioprosthesis (MVB ) are advantageous over mechanical devices as their incidence of thrombosis are significantly lower.**
- **However , the real prevalence of MVB thrombosis is unknown**

- ***Aim*: To determine the prevalence and predictors for MVB thrombosis**

# *Material & Methods:*

- 10 years: 156 pts: MVR
- 35/156 (22.4%): Bioprosthetic MVR
- Mean age: 68.7± 9.5
- *Valve Type* :




- *Etiology:* Ischemic 49% (17)
  Rheumatic 31% (11)
  Degenerative 17%(6)
  Endocarditis 3% (1)

- 35/156 (40%): Persistent AF – Rx - Coumadin

# *Results:*

- 3/35 (8.5%)- MVB Thrombi
- Mean period from surgery to index event: 40±18 months
- Sinus rhythm
- Ischemic etiology
- Echocardiography: LVEF <35% ***(p<0.05)***
- 2/3- Redo (s/p CABG)
- 1/3- Coumadin for life

# *Conclusions:*

- **MVB thrombosis is a relatively frequent cause of valve dysfunction.**
- **The predictor of this phenomenon was significantly reduced LVEF in pts with ischemic etiology.**
- **In this group the need for early and long term anticoagulation should be considered.**